AIMS/HYPOTHESIS: Maternal obesity increases the risk for large-for-gestational-age birth and excess newborn adiposity, which are associated with adverse long-term metabolic outcomes in offspring, probably due to effects mediated through the intrauterine environment. We aimed to characterise the maternal metabolic milieu associated with maternal BMI and its relationship to newborn birthweight and adiposity. METHODS: Fasting and 1 h serum samples were collected from 400 European-ancestry mothers in the Hyperglycaemia and Adverse Pregnancy Outcome Study who underwent an OGTT at ∼28 weeks gestation and whose offspring had anthropometric measurements at birth. Metabolomics assays were performed using biochemical analyses of conventional clinical metabolites, targeted MS-based measurement of amino acids and acylcarnitines and non-targeted GC/MS. RESULTS: Per-metabolite analyses demonstrated broad associations with maternal BMI at fasting and 1 h for lipids, amino acids and their metabolites together with carbohydrates and organic acids. Similar metabolite classes were associated with insulin resistance with unique associations including branched-chain amino acids. Pathway analyses indicated overlapping and unique associations with maternal BMI and insulin resistance. Network analyses demonstrated collective associations of maternal metabolite subnetworks with maternal BMI and newborn size and adiposity, including communities of acylcarnitines, lipids and related metabolites, and carbohydrates and organic acids. Random forest analyses demonstrated contribution of lipids and lipid-related metabolites to the association of maternal BMI with newborn outcomes. CONCLUSIONS/ INTERPRETATION: Higher maternal BMI and insulin resistance are associated with broad-based changes in maternal metabolites, with lipids and lipid-related metabolites accounting, in part, for the association of maternal BMI with newborn size at birth.
AIn class="Disease">MS/HYPOTHESIS: Maternal obesity increases the risk for large-for-gestational-age birth and excess newborn adiposity, which are associated with adverse long-term metabolic outcomes in offspring, probably due to effects mediated through the intrauterine environment. We aimed to characterise the maternal metabolic milieu associated with maternal BMI and its relationship to newborn birthweight and adiposity. METHODS: Fasting and 1 h serum samples were collected from 400 European-ancestry mothers in the Hyperglycaemia and Adverse Pregnancy Outcome Study who underwent an OGTT at ∼28 weeks gestation and whose offspring had anthropometric measurements at birth. Metabolomics assays were performed using biochemical analyses of conventional clinical metabolites, targeted MS-based measurement of amino acids and acylcarnitines and non-targeted GC/MS. RESULTS: Per-metabolite analyses demonstrated broad associations with maternal BMI at fasting and 1 h for lipids, amino acids and their metabolites together with carbohydrates and organic acids. Similar metabolite classes were associated with insulin resistance with unique associations including branched-chain amino acids. Pathway analyses indicated overlapping and unique associations with maternal BMI and insulin resistance. Network analyses demonstrated collective associations of maternal metabolite subnetworks with maternal BMI and newborn size and adiposity, including communities of acylcarnitines, lipids and related metabolites, and carbohydrates and organic acids. Random forest analyses demonstrated contribution of lipids and lipid-related metabolites to the association of maternal BMI with newborn outcomes. CONCLUSIONS/ INTERPRETATION: Higher maternal BMI and insulin resistance are associated with broad-based changes in maternal metabolites, with lipids and lipid-related metabolites accounting, in part, for the association of maternal BMI with newborn size at birth.
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Denise M Scholtens; Michael J Muehlbauer; Natalie R Daya; Robert D Stevens; Alan R Dyer; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; James R Bain; William L Lowe Journal: Diabetes Care Date: 2013-08-29 Impact factor: 19.112
Authors: Michael Nodzenski; Michael J Muehlbauer; James R Bain; Anna C Reisetter; William L Lowe; Denise M Scholtens Journal: Bioinformatics Date: 2014-07-29 Impact factor: 6.937
Authors: Marcus T Dittrich; Gunnar W Klau; Andreas Rosenwald; Thomas Dandekar; Tobias Müller Journal: Bioinformatics Date: 2008-07-01 Impact factor: 6.937
Authors: Denise M Scholtens; James R Bain; Anna C Reisetter; Michael J Muehlbauer; Michael Nodzenski; Robert D Stevens; Olga Ilkayeva; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; William L Lowe Journal: Diabetes Date: 2016-04-05 Impact factor: 9.461
Authors: Aleksandra Jelena Vidakovic; Vincent W V Jaddoe; Olta Gishti; Janine F Felix; Michelle A Williams; Albert Hofman; Hans Demmelmair; Berthold Koletzko; Henning Tiemeier; Romy Gaillard Journal: Eur J Epidemiol Date: 2015-12-14 Impact factor: 8.082
Authors: Jennifer L LaBarre; Carolyn F McCabe; Tamara R Jones; Peter Xk Song; Steven E Domino; Marjorie C Treadwell; Dana C Dolinoy; Vasantha Padmanabhan; Charles F Burant; Jaclyn M Goodrich Journal: Epigenomics Date: 2020-12-08 Impact factor: 4.778
Authors: Robert W McGarrah; Scott B Crown; Guo-Fang Zhang; Svati H Shah; Christopher B Newgard Journal: Circ Res Date: 2018-04-27 Impact factor: 17.367
Authors: Heidi Dutton; Sarah Jean Borengasser; Laura Marie Gaudet; Linda A Barbour; Erin Joanne Keely Journal: Med Clin North Am Date: 2018-01 Impact factor: 5.456